Today's Date: February 24, 2021
ViacomCBS Unveils Comprehensive Streaming Strategy and Expansive Slate of Originals Headed to Paramount+   •   Wells Fargo Donates $500,000 for Winter Storm Relief in Texas   •   Brookdale Enters into Definitive Agreement to Sell a Majority Stake in its Home Health, Hospice and Outpatient Therapy business   •   Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The   •   NOVA Recognized Nationally as Premier 2021-2022 Military Friendly® School   •   MemorialCare Saddleback Medical Center Earns Elite Honor for Maternity Care   •   Brookdale Announces Fourth Quarter and Full Year 2020 Results   •   Grunt Style Officially Licensed to Sell Air Force and Space Force Apparel   •   Canada and Délı̨nę Got'ı̨nę Government sign historic Governance Agreement in support of th   •   Martin Luther King, Jr.’s Only Grandchild Joins Impact Podcast for Special Black History Month Episode   •   Healthcare is failing its own diversity test, Leverage Network finds   •   BioLife Plasma Services Announces Expansion of Plasma Donation Centers Into California   •   The Change Company Welcomes Chris Gardner to its Board   •   Toyota Pledges $1 Million To Support Texans Impacted By Historic Winter Storm   •   CHS Board announces Retirement of CEO Joseph M. Catania   •   Revolve Group Announces Fourth Quarter and Full Year 2020 Financial Results   •   Susan G. Komen® Urges Women to Continue to Get Mammograms   •   The Alzheimer's Drug Discovery Foundation Appoints Karen Harris, Chief Financial Officer, and Dr. Mark Forman, Senior Director o   •   Opus Interactive Kicks Off 25th Year Expanding Territory, Support, and Automation   •   Bank of America Provides $1.1 Million to Support Texans and Communities Impacted by Winter Storm
Bookmark and Share

TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021

BOCA RATON, Fla. , February 23 /Businesswire/ - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2020 financial results on Tuesday, March 2, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.

Conference Call & Audio Webcast Details

Date

Tuesday, March 2, 2021

Time

8:30 a.m. ET

Telephone Access: U.S. and Canada

866-665-9531

Telephone Access: International

724-987-6977

Access Code For All Callers

6184646

Live Audio Webcast

www.therapeuticsmd.com

See Home Page or “Investors & Media” Section

A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 6184646.

About TherapeuticsMD

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefore; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and the proceeds that may be generated by such divestiture; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.


STORY TAGS: Webcast, Conference Call, Advisory, Earnings, Women, Other Health, Consumer, Health, Managed Care, United States, North America, Florida,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News